Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients.

在高风险固体器官移植受者中使用 Maribavir 治疗巨细胞病毒感染的真实世界经验。

• 影响指数: 4.423
• 发表时间: 2024 Jul
• 来源期刊: Open Forum Infect Dis
• DOI: 10.1093/ofid/ofae335
• PMID: 38957689
• 文章类型: Journal Article
• 中科院分区: Q3
• 方向: 医学
• 作者列表: Ni B,Wolfe CR,Arif S,Carugati M,Heldman MR,Messina JA,Miller RA,Saullo JL,Baker AW,Maziarz EK

关键词: antiviral drug resistance; antiviral therapy; cytomegalovirus; maribavir; solid organ transplantation

Abstract

We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.

摘要

我们评估了在13例实体器官移植受者中使用maribavir（MBV）治疗15例难治性/耐药性巨细胞病毒感染。由于治疗引起的MBV抵抗或MBV停药后的早期病毒学复发导致的治疗失败发生在7次（47％）发作中。在6次（40％）发作中实现了持续的病毒清除。